Ablative therapies for locoregional therapy of pancreatic neoplastic lesions developed during the last decade to be utilized throughout surgical procedure at the moment are turning into additionally obtainable to be utilized underneath endoscopic ultrasound (EUS) steerage. The benefit of this strategy is obvious due to the shut proximity of the EUS transducer to the goal lesion, coupled with developments of particularly designed ablation gadgets, making the process minimally invasive, and probably sparing sufferers from the morbidity of this methodology when carried out surgically.
EUS-guided ablative methods which were utilized to pancreatic neoplastic cysts, pancreatic useful and non-functional neuroendocrine neoplasms and pancreatic ductal adenocarcinoma embody ethanol injection, radiofrequency ablation (RFA), a mix of bipolar RFA and cryoablation, laser remedy (LT) and photodynamic remedy (PDT). To this point, most of those procedures have been utilized to sufferers at excessive surgical threat or who refused surgical procedure. Nevertheless, extra research evaluating a few of these therapies additionally in chosen sufferers not at surgical threat have gotten obtainable.
These research will pave the street to use this therapeutic strategy to a extra in depth variety of sufferers, alone or in affiliation with different therapies, corresponding to immunomodulating medication. The current manuscript will critically assessment the obtainable proof within the subject of EUS-guided native ablative therapy of strong and cystic pancreatic neoplasms. Exosomes (EXOs) are small vesicles (30-200 nm) of endocytic origin, that are launched by many various cell sorts into the extracellular house. They might play a key position in facilitating cell-cell communication, underneath each physiological and pathological situations.
EXOs include a variety of RNA molecules and proteins. Their particular molecular signatures make them promising candidates in early analysis and prognosis of pancreatic ailments. EXOs might additionally present a brand new methodology to observe therapy response in sufferers affected by pancreatic most cancers and different ailments of the pancreas. Moreover they might assist to enhance present therapies through customized drugs approaches utilizing them as therapeutic automobiles themselves.
The exploration of quantitative intra-tumoral metabolic heterogeneity in dual-time 18 F-FDG PET/CT of pancreatic most cancers
In complete, 183 PC sufferers have been analyzed retrospectively on this analysis. The standard metabolic parameters have been all statistically totally different between the early and delayed scans apart from metabolic tumor quantity (MTV). Within the radiomics, there have been 59 textural options. Nineteen of 59 texture options have been statistically totally different between the early and delayed scans. Options that have been greater than 10% totally different throughout two scans have been noticed in a considerable proportion of sufferers. Weak correlations have been solely discovered between MTV, TLG (Complete lesion glycolysis), SUVpeak and the RI of some texture options in early or delayed scans.
There have been clearly fewer options with important distinction in resectable PC group than in unresectable PC group. Most options displaying the distinction in unresectable group whereas no important distinction in resectable group. Options have been extracted based mostly on spatial distribution of 18F-FDG uptake in picture. Firstly, the feel options and the traditional metabolic parameters of the delayed scan have been each in contrast with that of the early scan. Statistically totally different knowledge was outlined amongst them. Secondly, the research evaluated the correlations between retention index (RI) of the feel options and the traditional metabolic parameters.
Lastly, the variation of texture options in dual-time PET/CT of resectable PC sufferers and unresectable PC sufferers was calculated individually. The mRNA expression profiles and corresponding clinicopathological data of PAC sufferers have been downloaded from The Most cancers Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) database, respectively. To additional discover the impact of hypoxia on the prognosis of sufferers with PAC in addition to the tumor immune microenvironment, we established a hypoxia threat mannequin and divided it into high- and low-risk teams according to the hypoxia threat rating.
Lengthy non-coding RNA PART1 predicts a poor prognosis and promotes the malignant development of pancreatic most cancers by sponging miR-122
qRT-PCR was utilized to detect PART1 expression in 45 instances of pancreatic most cancers sufferers. The chi-square check was carried out to evaluate the affiliation between PART1 expression and clinicopathologic options, and Kaplan-Meier methodology was utilized to guage total survival. In vitro CCK-8, transwell invasion, and circulation cytometry assays have been utilized to detect the results of PART1 on cell proliferation, invasion, and apoptosis, respectively. Luciferase reporter and RNA immunoprecipitation assays have been used to determine the regulatory mechanism between PART1 and miR-122. PART1 expression was upregulated in pancreatic most cancers tissues and cell traces.
Excessive PART1 expression was carefully correlated with tumor dimension, T classification, medical stage, and vascular invasion, and predicted a poor total survival. PART1 knockdown considerably suppressed cell proliferation and invasion skills of pancreatic most cancers however promoted cell apoptosis. PART1 was discovered to function a molecular sponge of miR-122, and miR-122 inhibition partially reversed the inhibitory phenotypes of PART1 knockdown on pancreatic most cancers cells. The Editor requested the authors for an evidence to account for the looks of strikingly comparable knowledge of their paper independently, though the authors by no means responded inside an affordable time to substantiate that the paper must be retracted.
Cancer/Testis Antigen 5.1 (SSX1) Antibody |
|
abx145140-1096tests |
Abbexa |
10 × 96 tests |
Ask for price |
Cancer/Testis Antigen 5.1 (SSX1) Antibody |
|
abx145140-596tests |
Abbexa |
5 × 96 tests |
Ask for price |
Cancer/Testis Antigen 5.1 (SSX1) Antibody |
|
abx145140-96tests |
Abbexa |
96 tests |
EUR 337.5 |
Cancer/Testis Antigen 5.1 (SSX1) Antibody |
|
abx238257-100g |
Abbexa |
100 µg |
EUR 350 |
Cancer/Testis Antigen 5.1 (SSX1) Antibody |
|
abx238257-100ug |
Abbexa |
100 ug |
EUR 661.2 |
|
|
Cancer/Testis Antigen 5.1 (SSX1) Antibody |
|
abx302290-100g |
Abbexa |
100 µg |
EUR 362.5 |
Cancer/Testis Antigen 5.1 (SSX1) Antibody |
|
20-abx302290 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 20 ug
- 50 ug
- 100 ug
- 200 ug
- 1 mg
|
|
|
Cancer/Testis Antigen 5.1 (SSX1) Antibody |
|
abx302290-20g |
Abbexa |
20 µg |
EUR 162.5 |
Cancer/Testis Antigen 5.1 (SSX1) Antibody |
|
abx302290-50g |
Abbexa |
50 µg |
EUR 250 |
Cancer/testis Antigen 2 (CTAG2) Antibody |
|
abx027593-400l |
Abbexa |
400 µl |
EUR 518.75 |
Cancer/testis Antigen 2 (CTAG2) Antibody |
|
abx027593-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
|
Cancer/testis Antigen 2 (CTAG2) Antibody |
|
abx027593-80l |
Abbexa |
80 µl |
EUR 250 |
|
|
Cancer/testis Antigen 2 (CTAG2) Antibody |
|
abx375499-96tests |
Abbexa |
96 tests |
EUR 337.5 |
Cancer/testis Antigen 2 (CTAG2) Antibody |
|
abx376324-96tests |
Abbexa |
96 tests |
EUR 225 |
Cancer/testis Antigen 2 (CTAG2) Antibody |
|
abx344921-100l |
Abbexa |
100 µl |
EUR 250 |
Cancer/testis Antigen 2 (CTAG2) Antibody |
|
abx344921-50l |
Abbexa |
50 µl |
EUR 187.5 |
Cancer/testis Antigen 2 (CTAG2) Antibody |
|
20-abx149592 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
|
Cancer/Testis Antigen 1A (CTAG1A) Antibody |
|
abx027441-400l |
Abbexa |
400 µl |
EUR 518.75 |
Cancer/Testis Antigen 1A (CTAG1A) Antibody |
|
abx027441-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
|
Cancer/Testis Antigen 1A (CTAG1A) Antibody |
|
abx027441-80l |
Abbexa |
80 µl |
EUR 281.25 |
|
|
Cancer/Testis Antigen 1A (CTAG1A) Antibody |
|
abx111352-100l |
Abbexa |
100 µl |
EUR 612.5 |
Cancer/Testis Antigen 1A (CTAG1A) Antibody |
|
20-abx111352 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
|
Cancer/Testis Antigen 1A (CTAG1A) Antibody |
|
abx331930-100ul |
Abbexa |
100 ul |
EUR 510 |
|
|
Cancer/Testis Antigen 1B (CTAG1B) Antibody |
|
abx135754-100tests |
Abbexa |
100 tests |
EUR 175 |
Cancer/Testis Antigen 1B (CTAG1B) Antibody |
|
20-abx135754 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 20 ul
- 50 ul
- 100 ul
- 200 ul
|
|
|
Cancer/Testis Antigen 1 (CTAG1B) Antibody |
|
abx433062-100g |
Abbexa |
100 µg |
EUR 387.5 |
Cancer/Testis Antigen 1B (CTAG1B) Antibody |
|
20-abx171540 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
|
Cancer/Testis Antigen 1B (CTAG1B) Antibody |
|
abx171540-1ml |
Abbexa |
1 ml |
EUR 787.5 |
Cancer/Testis Antigen 1A (CTAG1A) Antibody |
|
20-abx126874 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
|
Cancer/Testis Antigen 1B (CTAG1B) Antibody |
|
abx128209-100l |
Abbexa |
100 µl |
EUR 275 |
Cancer/Testis Antigen 1B (CTAG1B) Antibody |
|
20-abx128209 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10 ug
- 50 ug
- 100 ug
- 200 ug
- 1 mg
|
|
|
Cancer/Testis Antigen 1B (CTAG1B) Antibody |
|
abx128209-1ml |
Abbexa |
1 ml |
EUR 750 |
Cancer/Testis Antigen 1B (CTAG1B) Antibody |
|
abx128209-200l |
Abbexa |
200 µl |
EUR 337.5 |
Cancer/Testis Antigen 5.1 (SSX1) Antibody (HRP) |
|
abx316206-100g |
Abbexa |
100 µg |
EUR 362.5 |
Cancer/Testis Antigen 5.1 (SSX1) Antibody (HRP) |
|
20-abx316206 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 20 ug
- 50 ug
- 100 ug
- 200 ug
- 1 mg
|
|
|
Cancer/Testis Antigen 5.1 (SSX1) Antibody (HRP) |
|
abx316206-20g |
Abbexa |
20 µg |
EUR 162.5 |
Cancer/Testis Antigen 5.1 (SSX1) Antibody (HRP) |
|
abx316206-50g |
Abbexa |
50 µg |
EUR 250 |
Cancer/Testis Antigen 5.1 (SSX1) Antibody (FITC) |
|
abx316207-100g |
Abbexa |
100 µg |
EUR 362.5 |
Cancer/Testis Antigen 5.1 (SSX1) Antibody (FITC) |
|
20-abx316207 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 20 ug
- 50 ug
- 100 ug
- 200 ug
- 1 mg
|
|
|
Cancer/Testis Antigen 5.1 (SSX1) Antibody (FITC) |
|
abx316207-20g |
Abbexa |
20 µg |
EUR 162.5 |
Cancer/Testis Antigen 5.1 (SSX1) Antibody (FITC) |
|
abx316207-50g |
Abbexa |
50 µg |
EUR 250 |
Cancer/Testis Antigen 5.1 (SSX1) Antibody (Biotin) |
|
abx316208-100g |
Abbexa |
100 µg |
EUR 362.5 |
Cancer/Testis Antigen 5.1 (SSX1) Antibody (Biotin) |
|
20-abx316208 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 20 ug
- 50 ug
- 100 ug
- 200 ug
- 1 mg
|
|
|
Cancer/Testis Antigen 5.1 (SSX1) Antibody (Biotin) |
|
abx316208-20g |
Abbexa |
20 µg |
EUR 162.5 |
Cancer/Testis Antigen 5.1 (SSX1) Antibody (Biotin) |
|
abx316208-50g |
Abbexa |
50 µg |
EUR 250 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) |
|
MBS6002009-02mL |
MyBiosource |
0.2(mL |
EUR 695 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) |
|
MBS6002009-5x02mL |
MyBiosource |
5x0.2mL |
EUR 2975 |
ARMC3 (Cancer/testis antigen 81) Polyclonal Antibody |
|
MBS9238385-01mL |
MyBiosource |
0.1mL |
EUR 415 |
ARMC3 (Cancer/testis antigen 81) Polyclonal Antibody |
|
MBS9238385-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1841 |
Cancer/Testis Antigen 1B (CTAG1B) Polyclonal Antibody |
|
CAU21749-100ul |
Biomatik Corporation |
100ul |
EUR 235.2 |
Cancer/Testis Antigen 1B (CTAG1B) Polyclonal Antibody |
|
CAU21749-200ul |
Biomatik Corporation |
200ul |
EUR 294 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (AP) |
|
MBS6289627-02mL |
MyBiosource |
0.2mL |
EUR 980 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (AP) |
|
MBS6289627-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (APC) |
|
MBS6289628-02mL |
MyBiosource |
0.2mL |
EUR 980 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (APC) |
|
MBS6289628-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (FITC) |
|
MBS6289630-02mL |
MyBiosource |
0.2mL |
EUR 980 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (FITC) |
|
MBS6289630-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (PE) |
|
MBS6289637-02mL |
MyBiosource |
0.2mL |
EUR 980 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (PE) |
|
MBS6289637-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (Biotin) |
|
MBS6289629-02mL |
MyBiosource |
0.2mL |
EUR 980 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (Biotin) |
|
MBS6289629-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (MaxLight 405) |
|
MBS6289632-01mL |
MyBiosource |
0.1mL |
EUR 980 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (MaxLight 405) |
|
MBS6289632-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (MaxLight 490) |
|
MBS6289633-01mL |
MyBiosource |
0.1mL |
EUR 980 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (MaxLight 490) |
|
MBS6289633-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (MaxLight 550) |
|
MBS6289634-01mL |
MyBiosource |
0.1mL |
EUR 980 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (MaxLight 550) |
|
MBS6289634-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (MaxLight 650) |
|
MBS6289635-01mL |
MyBiosource |
0.1mL |
EUR 980 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (MaxLight 650) |
|
MBS6289635-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (MaxLight 750) |
|
MBS6289636-01mL |
MyBiosource |
0.1mL |
EUR 980 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (MaxLight 750) |
|
MBS6289636-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (Azide free) (HRP) |
|
MBS6289631-02mL |
MyBiosource |
0.2mL |
EUR 980 |
CTAG2, ID (CTAG2, ESO2, LAGE1, Cancer/testis antigen 2, Autoimmunogenic cancer/testis antigen NY-ESO-2, Cancer/testis antigen 6.2, L antigen family member 1) (Azide free) (HRP) |
|
MBS6289631-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
Polyclonal Antibody to Cancer/Testis Antigen 1B (CTAG1B) |
|
MBS2026997-01mL |
MyBiosource |
0.1mL |
EUR 175 |
Polyclonal Antibody to Cancer/Testis Antigen 1B (CTAG1B) |
|
MBS2026997-02mL |
MyBiosource |
0.2mL |
EUR 220 |
Polyclonal Antibody to Cancer/Testis Antigen 1B (CTAG1B) |
|
MBS2026997-05mL |
MyBiosource |
0.5mL |
EUR 355 |
Polyclonal Antibody to Cancer/Testis Antigen 1B (CTAG1B) |
|
MBS2026997-1mL |
MyBiosource |
1mL |
EUR 435 |
Polyclonal Antibody to Cancer/Testis Antigen 1B (CTAG1B) |
|
MBS2026997-5mL |
MyBiosource |
5mL |
EUR 1185 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) |
|
MBS645319-02mL |
MyBiosource |
0.2mL |
EUR 695 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) |
|
MBS645319-5x02mL |
MyBiosource |
5x0.2mL |
EUR 2975 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (AP) |
|
MBS6289616-02mL |
MyBiosource |
0.2mL |
EUR 980 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (AP) |
|
MBS6289616-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (APC) |
|
MBS6289617-02mL |
MyBiosource |
0.2mL |
EUR 980 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (APC) |
|
MBS6289617-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (Biotin) |
|
MBS6289618-02mL |
MyBiosource |
0.2mL |
EUR 980 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (Biotin) |
|
MBS6289618-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (FITC) |
|
MBS6289619-02mL |
MyBiosource |
0.2mL |
EUR 980 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (FITC) |
|
MBS6289619-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (PE) |
|
MBS6289626-02mL |
MyBiosource |
0.2mL |
EUR 980 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (PE) |
|
MBS6289626-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
Cancer/Testis Antigen 1B (CTAG1B) Polyclonal Antibody (Human) |
|
4-PAJ316Hu01 |
Cloud-Clone |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 20ul
- 100ul
- 200ul
- 1ml
- 10ml
|
|
|
|
Description: A Rabbit polyclonal antibody against Human Cancer/Testis Antigen 1B (CTAG1B) |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) |
|
MBS6007563-01mg |
MyBiosource |
0.1(mg |
EUR 630 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) |
|
MBS6007563-5x01mg |
MyBiosource |
5x0.1mg |
EUR 2680 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (PE) |
|
MBS6157301-01mL |
MyBiosource |
0.1(mL |
EUR 875 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (PE) |
|
MBS6157301-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3800 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (AP) |
|
MBS6130786-01mL |
MyBiosource |
0.1(mL |
EUR 875 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (AP) |
|
MBS6130786-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3800 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) APC |
|
MBS6136089-01mL |
MyBiosource |
0.1(mL |
EUR 875 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) APC |
|
MBS6136089-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3800 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (HRP) |
|
MBS6151998-01mL |
MyBiosource |
0.1(mL |
EUR 875 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (HRP) |
|
MBS6151998-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3800 |
Human Cancer/testis antigen 2 (CTAG2) |
|
1-CSB-EP006127HU |
Cusabio |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10ug
- 50ug
- 100ug
- 200ug
- 500ug
- 1MG
|
|
|
|
Description: Recombinant Human Cancer/testis antigen 2(CTAG2) expressed in E.coli |
Human Cancer/testis antigen 2 (CTAG2) |
|
1-CSB-YP006127HUa4 |
Cusabio |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10ug
- 50ug
- 100ug
- 200ug
- 500ug
- 1MG
|
|
|
|
Description: Recombinant Human Cancer/testis antigen 2(CTAG2) expressed in Yeast |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (MaxLight 405) |
|
MBS6289621-01mL |
MyBiosource |
0.1mL |
EUR 980 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (MaxLight 405) |
|
MBS6289621-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (MaxLight 490) |
|
MBS6289622-01mL |
MyBiosource |
0.1mL |
EUR 980 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (MaxLight 490) |
|
MBS6289622-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (MaxLight 550) |
|
MBS6289623-01mL |
MyBiosource |
0.1mL |
EUR 980 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (MaxLight 550) |
|
MBS6289623-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (MaxLight 650) |
|
MBS6289624-01mL |
MyBiosource |
0.1mL |
EUR 980 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (MaxLight 650) |
|
MBS6289624-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (MaxLight 750) |
|
MBS6289625-01mL |
MyBiosource |
0.1mL |
EUR 980 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (MaxLight 750) |
|
MBS6289625-5x01mL |
MyBiosource |
5x0.1mL |
EUR 4250 |
Human Cancer/testis antigen 1 (CTAG1A) |
|
1-CSB-EP006125HU |
Cusabio |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10ug
- 50ug
- 100ug
- 200ug
- 500ug
- 1MG
|
|
|
|
Description: Recombinant Human Cancer/testis antigen 1(CTAG1A) expressed in E.coli |
Cancer/Testis Antigen 5.1 (SSX1) Protein |
|
abx262587-10mg |
Abbexa |
10 mg |
EUR 325 |
Cancer/Testis Antigen 5.1 (SSX1) Protein |
|
abx262587-25mg |
Abbexa |
25 mg |
EUR 6575 |
Cancer/Testis Antigen 5.1 (SSX1) Protein |
|
abx262587-5mg |
Abbexa |
5 mg |
EUR 225 |
Human Cancer/testis antigen 1 (CTAG1A) |
|
1-CSB-YP006125HU |
Cusabio |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 10ug
- 50ug
- 100ug
- 200ug
- 500ug
- 1MG
|
|
|
|
Description: Recombinant Human Cancer/testis antigen 1(CTAG1A) expressed in Yeast |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (Biotin) |
|
MBS6141392-01mL |
MyBiosource |
0.1(mL |
EUR 875 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (Biotin) |
|
MBS6141392-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3800 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (FITC) |
|
MBS6146695-01mL |
MyBiosource |
0.1(mL |
EUR 875 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (FITC) |
|
MBS6146695-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3800 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (Azide free) (HRP) |
|
MBS6289620-02mL |
MyBiosource |
0.2mL |
EUR 980 |
CTAG1A, NT (CTAG1A, CTAG, CTAG1, ESO1, LAGE2, LAGE2A, Cancer/testis antigen 1, Autoimmunogenic cancer/testis antigen NY-ESO-1, Cancer/testis antigen 6.1, L antigen family member 2) (Azide free) (HRP) |
|
MBS6289620-5x02mL |
MyBiosource |
5x0.2mL |
EUR 4250 |
Cancer/Testis Antigen 1B (CTAG1B) Polyclonal Antibody (Human), PE |
|
4-PAJ316Hu01-PE |
Cloud-Clone |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 20ul
- 100ul
- 200ul
- 1ml
- 10ml
|
|
|
|
Description: A Rabbit polyclonal antibody against Human Cancer/Testis Antigen 1B (CTAG1B). This antibody is labeled with PE. |
Cancer/Testis Antigen 1B (CTAG1B) Polyclonal Antibody (Human), APC |
|
4-PAJ316Hu01-APC |
Cloud-Clone |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 20ul
- 100ul
- 200ul
- 1ml
- 10ml
|
|
|
|
Description: A Rabbit polyclonal antibody against Human Cancer/Testis Antigen 1B (CTAG1B). This antibody is labeled with APC. |
Cancer/Testis Antigen 1B (CTAG1B) Polyclonal Antibody (Human), Cy3 |
|
4-PAJ316Hu01-Cy3 |
Cloud-Clone |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 20ul
- 100ul
- 200ul
- 1ml
- 10ml
|
|
|
|
Description: A Rabbit polyclonal antibody against Human Cancer/Testis Antigen 1B (CTAG1B). This antibody is labeled with Cy3. |
Cancer/Testis Antigen 1B (CTAG1B) Polyclonal Antibody (Human), HRP |
|
4-PAJ316Hu01-HRP |
Cloud-Clone |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 20ul
- 100ul
- 200ul
- 1ml
- 10ml
|
|
|
|
Description: A Rabbit polyclonal antibody against Human Cancer/Testis Antigen 1B (CTAG1B). This antibody is labeled with HRP. |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (MaxLight 550) |
|
MBS6210999-01mL |
MyBiosource |
0.1(mL |
EUR 875 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (MaxLight 550) |
|
MBS6210999-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3800 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (MaxLight 405) |
|
MBS6189649-01mL |
MyBiosource |
0.1(mL |
EUR 875 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (MaxLight 405) |
|
MBS6189649-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3800 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (MaxLight 750) |
|
MBS6232349-01mL |
MyBiosource |
0.1(mL |
EUR 875 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (MaxLight 750) |
|
MBS6232349-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3800 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (MaxLight 490) |
|
MBS6200324-01mL |
MyBiosource |
0.1(mL |
EUR 875 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (MaxLight 490) |
|
MBS6200324-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3800 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (MaxLight 650) |
|
MBS6221674-01mL |
MyBiosource |
0.1(mL |
EUR 875 |
CTAG2 (ESO2, LAGE1, Cancer/Testis Antigen 2, CT2, Autoimmunogenic Cancer/Testis Antigen NY-ESO-2, Cancer/Testis Antigen 6.2, CT6.2, L Antigen Family Member 1, LAGE-1, MGC138724, MGC3803) (MaxLight 650) |
|
MBS6221674-5x01mL |
MyBiosource |
5x0.1mL |
EUR 3800 |
Cancer/Testis Antigen 1B (CTAG1B) Polyclonal Antibody (Human), FITC |
|
4-PAJ316Hu01-FITC |
Cloud-Clone |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 20ul
- 100ul
- 200ul
- 1ml
- 10ml
|
|
|
|
Description: A Rabbit polyclonal antibody against Human Cancer/Testis Antigen 1B (CTAG1B). This antibody is labeled with FITC. |
Rabbit anti-human cancer/testis antigen 1A polyclonal Antibody |
|
MBS710901-01mL |
MyBiosource |
0.1mL |
EUR 485 |
Rabbit anti-human cancer/testis antigen 1A polyclonal Antibody |
|
MBS710901-5x01mL |
MyBiosource |
5x0.1mL |
EUR 2175 |
Recombinant Human Cancer/testis antigen 2 |
|
MBS1166239-002mgEColi |
MyBiosource |
0.02mg(E-Coli) |
EUR 255 |
The Editor has subsequently made the manager determination to retract this paper. The Editor apologizes to the readership for any inconvenience prompted. Thirty sufferers who underwent TP have been eligible for the research. Bowel motion frequency elevated over time, and the RBW and TSFT have been lowest by 1 12 months. The worldwide well being standing rating confirmed no important distinction over time.